Mustafa Hatipoglu
Military Medical Academy
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mustafa Hatipoglu.
Journal of Infection in Developing Countries | 2013
Vedat Turhan; Mesut Mutluoglu; Ali Acar; Mustafa Hatipoglu; Yalcin Onem; Gunalp Uzun; Hakan Ay; Oral Oncul; Levent Gorenek
INTRODUCTION In the present study, we sought to identify the bacterial organisms associated with diabetic foot infections (DFIs) and their antibiotic sensitivity profiles. METHODOLOGY We retrospectively reviewed the records of wound cultures collected from diabetic patients with foot infections between May 2005 and July 2010. RESULTS We identified a total of 298 culture specimens (165 [55%] wound swab, 108 [36%] tissue samples, and 25 [9%] bone samples) from 107 patients (74 [69%] males and 33 [31%] females, mean age 62 ± 13 yr) with a DFI. Among all cultures 83.5% (223/267) were monomicrobial and 16.4% (44/267) were polymicrobial. Gram-negative bacterial isolates (n = 191; 61.3%) significantly outnumbered Gram-positive isolates (n = 121; 38.7%). The most frequently isolated bacteria were Pseudomonas species (29.8%), Staphylococcus aureus (16.7%), Enterococcus species (11.5%), Escherichia coli (7.1%), and Enterobacter species (7.1%), respectively. While 13.2% of the Gram-negative isolates were inducible beta-lactamase positive, 44.2% of Staphylococcus aureus isolates were methicillin resistant. CONCLUSIONS Our results support the recent view that Gram-negative organisms, depending on the geographical location, may predominate in DFIs.
International Journal of Infectious Diseases | 2014
Hakan Erdem; Nazif Elaldi; Nefise Oztoprak; Gonul Sengoz; Oznur Ak; Selçuk Kaya; Asuman Inan; Saygın Nayman-Alpat; Aysegul Ulu-Kilic; Abdullah Umut Pekok; Alper Gunduz; Mustafa Gökhan Gözel; Filiz Pehlivanoglu; Kadriye Kart Yasar; Hava Yilmaz; Mustafa Hatipoglu; Gonul Cicek-Senturk; Fusun Zeynep Akcam; Ahmet Cagkan Inkaya; Esra Kazak; Ayşe Sagmak-Tartar; Recep Tekin; Derya Ozturk-Engin; Yasemin Ersoy; Oguz Resat Sipahi; Tumer Guven; Gunay Tuncer-Ertem; Selma Alabay; Ayhan Akbulut; Ilker Inanc Balkan
BACKGROUND The aim of this study was to delineate mortality indicators in pneumococcal meningitis with special emphasis on therapeutic implications. METHODS This retrospective, multicenter cohort study involved a 15-year period (1998-2012). Culture-positive cases (n=306) were included solely from 38 centers. RESULTS Fifty-eight patients received ceftriaxone plus vancomycin empirically. The rest were given a third-generation cephalosporin alone. Overall, 246 (79.1%) isolates were found to be penicillin-susceptible, 38 (12.2%) strains were penicillin-resistant, and 22 (7.1%) were oxacillin-resistant (without further minimum inhibitory concentration testing for penicillin). Being a critical case (odds ratio (OR) 7.089, 95% confidence interval (CI) 3.230-15.557) and age over 50 years (OR 3.908, 95% CI 1.820-8.390) were independent predictors of mortality, while infection with a penicillin-susceptible isolate (OR 0.441, 95% CI 0.195-0.996) was found to be protective. Empirical vancomycin use did not provide significant benefit (OR 2.159, 95% CI 0.949-4.912). CONCLUSIONS Ceftriaxone alone is not adequate in the management of pneumococcal meningitis due to penicillin-resistant pneumococci, which is a major concern worldwide. Although vancomycin showed a trend towards improving the prognosis of pneumococcal meningitis, significant correlation in statistical terms could not be established in this study. Thus, further studies are needed for the optimization of pneumococcal meningitis treatment.
Scandinavian Journal of Infectious Diseases | 2013
Gunalp Uzun; Yalcin Onem; Mustafa Hatipoglu; Turhan; Mesut Mutluoglu; Hakan Ay
Abstract Piperacillin/tazobactam (PTZ) is frequently used in patients with diabetic foot infections. Herein, we report a patient who developed severe neutropenia, thrombocytopenia, and fever while receiving PTZ for a diabetic foot infection. We recommend vigilance when long-term PTZ use is planned in patients with diabetic foot infections.
Journal of Diabetes and Its Complications | 2016
Mustafa Hatipoglu; Mesut Mutluoglu; Vedat Turhan; Gunalp Uzun; Benjamin A. Lipsky; Erol Sevim; Hayati Demiraslan; Esma Eryilmaz; Cem Ozuguz; Ali Memis; Hakan Ay; Bilgin Arda; Serhat Uysal; Vicdan Koksaldi Motor; Cigdem Kader; Ayşe Ertürk; Omer Coskun; Fazilet Duygu; S. Guler; Fatma Aybala Altay; Aziz Ogutlu; Sibel Bolukcu; Senol Yildiz; Özlem Kandemir; Halide Aslaner; Arife Polat; Mustafa Kasım Karahocagil; Kadriye Kart Yasar; Emine Sehmen; Sirri Kilic
AIM Clinical practice guidelines for the management of diabetic foot infections developed by the Infectious Diseases Society of America (IDSA) are commonly used worldwide. The issue of whether or not these guidelines need to be adjusted for local circumstances, however, has seldom been assessed in large prospective trials. METHODS The Turk-DAY trial was a prospective, multi-center study in which infectious disease specialists from centers across Turkey were invited to participate (NCT02026830). RESULTS A total of 35 centers throughout Turkey enrolled patients in the trial. Overall, investigators collected a total of 522 specimens from infected diabetic foot wounds for culture from 447 individual patients. Among all isolates, 36.4% were gram-positive organisms, with Staphylococcus aureus the most common among these (11.4%). Gram-negative organisms constituted 60.2% of all the isolates, and the most commonly isolated gram-negative was Escherichia coli (15%). The sensitivity rates of the isolated species were remarkably low for several antimicrobials used in the mild infection group. CONCLUSIONS Based on our findings, several of the antimicrobials frequently used for empirical treatment, including some also recommended in the IDSA guidelines, would not be optimal for treating diabetic foot infections in Turkey. Although the IDSA guideline recommendations may be helpful to guide empiric antimicrobial therapy of DFIs, they should be adjusted to local conditions.
European Journal of Clinical Microbiology & Infectious Diseases | 2014
Mustafa Hatipoglu; Mesut Mutluoglu; G. Uzun; E. Karabacak; Vedat Turhan; Benjamin A. Lipsky
Health and Quality of Life Outcomes | 2016
Zehra Karacaer; Banu Cakir; Hakan Erdem; Kenan Ugurlu; Gul Durmus; Nevin Ince; Cinar Ozturk; Rodrigo Hasbun; Ayse Batirel; Esmeray Mutlu Yilmaz; Ilkay Bozkurt; Mustafa Sunbul; Aynur Aynioglu; Aynur Atilla; Ayse Erbay; Ayse Inci; Çiğdem Kader; Elif Tukenmez Tigen; Gokhan Karaahmetoglu; Seher Ayten Coskuner; Ebru Dik; Huseyin Tarakci; Selma Tosun; Fatime Korkmaz; Servet Kolgelier; Fatma Yilmaz Karadag; Serpil Erol; Kamuran Turker; Ceyda Necan; Ahmet Melih Sahin
Clinical Infectious Diseases | 2016
Mustafa Hatipoglu; Vedat Turhan
The Journal of Infectious Diseases | 2014
Ergenekon Karagoz; Mustafa Hatipoglu; Vedat Turhan
Disease and Molecular Medicine | 2016
Seyid Ahmet Ay; Yusuf Hançerli; Secil Deniz; Muzaffer Saglam; Ferhat Deniz; Mustafa Hatipoglu; Veysel Ozalper; Arif Yonem; Asim Ulcay; Kamil Baskoy
Annals of Clinical Microbiology and Antimicrobials | 2015
Hava Yilmaz; Vedat Turhan; Kadriye Kart Yasar; Mustafa Hatipoglu; Mustafa Sunbul; Hakan Leblebicioglu